About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Current Press Releases

Archived Press Releases

Press Releases image

Archived Press Releases

February 23, 2004

Onyvax Appoints Dr John Brown As Non Executive Director

London, UK – 23 February, 2004: Onyvax Limited, the biotechnology company developing novel cancer therapies, today announces the appointment of Dr John Brown as non-executive director with immediate effect.

John was, until recently, Chief Executive of Acambis, the FTSE 250 biotech company which specialises in the development of vaccines to prevent and treat infectious diseases, and is recognised internationally as the foremost producer of smallpox and traveller vaccines. John joined Acambis as Finance Director in 1995, taking the company through its float in the same year, before being appointed to CEO in March 1997. He led the company from its early-stages through to product commercialisation, which resulted in successful bids for a number of smallpox vaccine supply contracts, including that of the US Government in 2001. During John’s time at Acambis, the company grew from 29 to 325 employees and achieved profitability in 2002.

Prior to joining Acambis, John spent four years in equity research, latterly as Head of Research at Sutherland and Partners. Prior to that, he was at PA Consulting, where he advised on the tie-ups between Roche and Genentech, and Marion Laboratories and Merrell Dow. John’s early career included five years at Glaxo Group Research where he published extensively on neuropeptides antagonists. John holds an MBA and a PhD in neuropharmacology. He is currently Chairman of the Roslin Institute, Edinburgh.

Commenting on the appointment, Dr. Anthony Walker, CEO of Onyvax, said: “I am delighted to welcome John to the Onyvax Board. John brings invaluable biotechnology experience and in particular an unparalleled knowledge of the vaccine industry. He will be a great asset to Onyvax as we advance our pipeline.”

On his appointment, John Brown said: “Onyvax is an exciting emerging biotech company which has achieved encouraging clinical results with its cancer vaccines. My role will be to support management in exploiting the Company's enormous potential and I very much look forward to the challenges ahead.”

For further information, please contact:

Dr Anthony Walker / Rob Johnson
+44 (0)20 8682 9119

Financial Dynamics
David Yates / Lucy Briggs
+44 (0)20 7831 3113

- Ends -

Notes to Editors:

Onyvax Ltd is a biotechnology company developing novel cancer therapies that harness the selective power of the immune system to seek and destroy tumour cells.

Founded in 1997, Onyvax has three product candidates in clinical trials designed for the treatment of prostate and other cancers. Onyvax’s lead products are based on combinations of inactivated cell lines that induce immune responses to a broad spectrum of tumour targets. Onyvax-P, a Cell Vaccine for prostate cancer, is due to enter Phase III clinical trials within 12 months. For each cancer type, Onyvax generates banks of proprietary cell lines representative of different stages of the disease. The vaccines are manufactured in bulk under standardised conditions.

Onyvax is committed to the commercialisation of new therapies that significantly prolong survival while maintaining a high quality of life for cancer patients. The Company is based in London and has collaborations with leading institutions in Europe and the US.

Further information on Onyvax can be found at www.onyvax.com


Back to Current Releases Back to Current Releases

© 1998-2009 Onyvax Ltd. All Rights Reserved